AzTrials
AzTrials

GlaucomaLYNXNCT01265719

Long-Term Non-Interventional Latanoprost Study

An observational study of Glaucoma and Ocular Hypertension, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 29 sites in 14 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a non-interventional, prospective, longitudinal cohort study. A total of 150 pediatric subjects with glaucoma or elevated intraocular pressure, including 75 latanoprost-treated subjects and 75 non-topical prostaglandin analogue treated subjects, will be enrolled from ophthalmic hospital clinics and academic… Read more about this study

Who is it for?
Ages 1 day to 17 years
Conditions the study is for
Glaucoma, Ocular Hypertension
How many people
175 participants
Where
29 sitesin 14 countries
Study dates
Dec 2010to Feb 2016
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 day to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Study population: Pediatric populations diagnosed with glaucoma or elevated intraocular pressure

Who may be able to join

  • Male or female <18 years of age (neonates must be at least 36 weeks gestational age).
  • Diagnosis of pediatric glaucoma or elevated intraocular pressure.
  • Evidence of a personally signed and dated informed consent document indicating that the subject (and/or a legally acceptable representative) has been informed of all pertinent aspects of the study. A signed and dated assent will be required where applicable according to local laws.
  • For treated subjects only:
  • Continuously treated with latanoprost for at least 1 month within the year prior to the baseline examination.
  • For untreated subjects only:
  • Continuously treated with latanoprost or other topical prostaglandin analogues for less than one month prior to the baseline examination (based on the best knowledge of treating ophthalmologists), and unlikely to be treated with latanoprost or other topical prostaglandin analogues during the three-year study period; OR
  • No prior treatment with latanoprost or other topical prostaglandin analogues, and unlikely to be treated with latanoprost or other topical prostaglandin analogues during the three-year study period.

Who cannot join

  • Unable/unwilling to comply with protocol.
  • Pregnant or nursing females at baseline.
  • For treated subjects only: a history of allergy or hypersensitivity to any of the ingredients contained in latanoprost (e.g., hypersensitivity to benzalkonium chloride).

Trial locations and contacts

29 sites in 14 countries.

29 sites in 14 countries

Italy4 sites
  • Azienda Ospedaliero Univ.

    Catania, CT, 95123

  • Ospedale Pediatrico Bambino Gesu

    Fiumicino (Roma), 00050

  • Istituto Giannina Gaslini, Divisione di Oculistica

    Genova, 16147

  • Unita' Operativa di Oculistica Pediatrica, Azienda Ospedaliera Ospedale Niguarda Ca'Grande

    Milan, 20162

Other trials in Italy

Spain4 sites
  • Hospital Sant Joan de Deu

    Esplugues de Llobregat, Barcelona, 08950

  • Hospital Clinico San Carlos

    Madrid, 28040

  • Hospital Virgen Del Rocio

    Seville, 41013

  • Hospital Universitario Miguel Servet

    Zaragoza, 50009

Other trials in Spain

France3 sites
  • CHU d'Amiens -Centre Saint Victor

    Amiens, 80000

  • Hopital Claude Huriez

    Lille, 59037

  • Fondation Ophtalmologique Adolphe de Rothschild

    Paris, Cedex 19, 75940

Other trials in France

Germany3 sites
  • Universitaetsklinikum Giessen und Marburg

    Giessen, 35392

  • Universitaetsklinikum Hamburg-Eppendorf

    Hamburg, 20246

  • Universitaetsklinikum Mainz

    Mainz, 55131

Other trials in Germany

United Kingdom3 sites
  • Birmingham and Midland Eye Centre, Consultant Ophthalmologist

    Birmingham, B18 7QH

  • Richard Desmond Childrens Eye Centre

    London, EC1V 2PD

  • Manchester Royal Eye Hospital

    Manchester, GT MAN, M13 9WH

Other trials in United Kingdom

Belgium2 sites
  • Universitair Ziekenhuis Antwerpen, Dienst Oftalmologie

    Edegem, 2650

  • Universitair Ziekenhuis Leuven - Campus Sint-Raphaël

    Leuven, 3000

Other trials in Belgium

Czechia2 sites
  • Fakultni nemocnice Brno

    Brno, 613 00

  • Fakultni nemocnice v Motole

    Prague, 150 06

Other trials in Czechia

Sweden2 sites
  • Akademiska Sjukhuset

    Uppsala, 751 85

  • Ögonkliniken, Centrallasarettet

    Västerås, 721 89

Other trials in Sweden

Colombia1 site
  • Clinica de Oftalmologia San Diego

    Medellín, Antioquia, 050016

Other trials in Colombia

Denmark1 site
  • Rigshospitalet - Glostrup

    Glostrup Municipality, 2600

Other trials in Denmark

Greece1 site
  • University General Hospital of Thessaloniki AHEPA

    Thessaloniki, 54636

Other trials in Greece

Peru1 site
  • Óptima Visión

    Miraflores, Lima region, L 18

Other trials in Peru

Portugal1 site
  • AIBILI - Associação para a Investigação Biomédica e Inovação em Luz e Imagem

    Coimbra, 3000-548

Other trials in Portugal

Slovakia1 site
  • Detska Fakultna nemocnica s poliklinikou Bratislava

    Bratislava, 83340

Other trials in Slovakia

About this study

Official title: A Prospective, Non-interventional, Longitudinal Cohort Study To Evaluate The Long-term Safety Of Latanoprost Treatment In Pediatric Populations

This is a non-interventional, prospective, longitudinal cohort study. A total of 150 pediatric subjects with glaucoma or elevated intraocular pressure, including 75 latanoprost-treated subjects and 75 non-topical prostaglandin analogue treated subjects, will be enrolled from ophthalmic hospital clinics and academic ophthalmic centers. As a non-interventional study, the study subjects' continued use of latanoprost and assessments of ocular events will be obtained through the routine medical follow-up with treating ophthalmologists or other designated members of the medical care team.

Read the detailed description

At least 40 subjects in each of the following age groups: 1-<5 years and 5-<18 years. No minimum required numbers in the <1 year age group.

Being tested
No intervention other than routine medical care
Keywords
Prospective, non-interventional, longitudinal, cohort study
Medical subject headings
Glaucoma, Ocular Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • No intervention other than routine medical careOther

    Also called Observational

    Subjects continuously treated with Latanoprost for at least one month Latanoprost treatment during the study period.

  • No intervention other than routine medical careOther

    Also called Observational

    Subjects not treated with any topical prostaglandin analogues or continuously treated with topical prostaglandin analogues for less than one month before the baseline examination, and unlikely to be treated with topical prostaglandin analogues during the study period.

Study groups in NCT01265719
Study groupRoleWhat they receive
Latanoprost-treatment groupNot described
Receives: Other: No intervention other than routine medical care
Non-topical prostaglandin analogue treatment groupNot described
Receives: Other: No intervention other than routine medical care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline to Last Available Observation in Best Corrected Visual Acuity (BCVA) (Snellen or Equivalent)

    Patients familiar with the letters of the alphabet were evaluated using Snellen visual acuity. Patients who were unable or unfamiliar with the letters of the alphabet were evaluated using charts made up of numbers, pictures (eg, Schering's Children's Eye Chart or Allen Cards), E's, or Landolt's broken rings, and other methods which were equivalent to Snellen acuity eg, HOTV testing).

    Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

Secondary outcomes (13)
  1. Number of Participants With Clinically Meaningful Change in Refractive Error

    The refractive error [cycloplegic where appropriate (eg, those unable to cooperate with manifest refraction)] were determined at the baseline visit and assessed at the following visits.

    Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

  2. Change From Baseline to Last Available Observation in Horizontal Corneal Diameter (by Caliper and/or Ruler)

    The horizontal corneal diameter was measured along the horizontal meridians. Diameter was measured using either a series of transparent plates with holes of different diameters in quarter-millimeter increments or with calibrated calipers compared against a ruler. When using calipers, the corneal diameter measurement was taken from limbus to a similar point 180° away at the opposite limbus. When not examining the children with anesthesia, it was recommended to use a tape measure across the head while measuring horizontal corneal diameter by photographic method.

    Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

  3. Change From Baseline to Last Available Observation in Intraocular Pressure (IOP)

    IOP was preferably measured using 1 of 3 applanation-contact methods: Goldmann applanation tonometry, Perkins tonometry, or TonoPen® (tonometry). iCare® rebound tonometer was also allowed if it was used consistently throughout the study.

    Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

  4. Cup-to-disc Ratio (for Assessment of Optic Nerve Changes/Structures) - Number of Participants With Clinically Significant Deterioration in Cup/Disc Ratios

    The cup/disc ratio was recorded horizontally and vertically for each examination, and reported in 0.1 increments.

    Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

  5. Visual Field Defects - Number of Participants With Clinically Significant Deterioration of Visual Field Defects.

    A visual field examination was performed for those patients who can cooperate automated perimetry utilizing a threshold program. All visual fields was conducted utilizing the standard white background with a Goldmann size III white stimulus. For those patients who can not perform formal visual field testing, then field to confrontation test was used for younger, non-verbal children, central, steady and maintains fixation was used.

    Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

  6. Iris Color Darkening

    Changes from baseline in iris color were reported at each follow-up visit. Photographs were taken at the discretion of investigators as per standard of care.

    Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

  7. Localized Pigmentation (Nevi or Freckles) of Conjunctiva, Iris and Choroid

    Changes from baseline in localized pigmentation (nevi and freckles) of the conjunctiva, iris and choroid were reported at each follow-up visit. Photographs were taken at the discretion of investigators as per standard of care.

    Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

  8. Eyelash Darkening/Thickening

    Changes from baseline in eyelash darkening/thickening/lengthening were reported at each follow-up visit. Photographs were taken at the discretion of investigators as per standard of care.

    Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

  9. Change From Baseline to Last Available Observation in Length of Eyelash (by Caliper and/or Ruler)

    The longest eyelash (mm) measured by caliper or ruler was recorded at baseline and each follow-up visit.

    Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

  10. Change From Baseline to Last Available Observation in Corneal Thickness (Pachymeter)

    Central corneal thickness was measured using a calibrated pachymeter, preferably an ultrasonic pachymeter.

    Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

  11. Conjunctival/Ocular Hyperemia

    Conjunctiva hyperemia was assessed by slit-lamp examination. When slit-lamp examination is not possible due to subject cooperation, a fixation light and 20-diopter lens (for magnification) was used to assess this parameter. Conjunctival hyperemia was assessed and graded by ophthalmologist at baseline and follow-up visits from grades 0-3 and is as follows:

    0 = None, Normal: few vessels of palpebral or bulbar conjunctiva easily observed

    1. = Mild, Reddening of the palpebral or bulbar conjunctiva
    2. = Moderate, Bright reddening of the palpebral or bulbar conjunctiva
    3. = Severe, Deep, bright, and diffuse reddening of the palpebral or bulbar conjunctiva

    Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

  12. Number of Participants With a Change in Anterior Segment Biomicroscopy

    Slit-lamp biomicroscopy (mounted or hand-held) without fluorescein and without dilation of the pupil was performed. When slit-lamp examination was not possible, a fixation light and 20-diopter lens (for magnification) was used. At each scheduled visit, deposition of pigment on the corneal endothelial layer or the lens capsule or any abnormalities of the lids, conjunctivae, cornea, anterior chamber, iris, or lens was examined.

    Measured: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months

  13. Number of Participants With Abnormalities in Fundoscopy Posterior Segment at Baseline

    Fundoscopy was performed after dilation of the pupils (eg, 1 % tropicamide or cyclopentolate and 2 ½ % phenylephrine, or a clinically- appropriate dose according to the clinician's standard care of each particular patient). The examination included an evaluation of the vitreous body, retina (including the macula), and optic nerve head.

    The fundoscopy e-CRF was completed only at baseline because the investigators were required to perform slit lamp, direct or indirect ophthalmoscopy at each visit and report any AEs observed which included the vitreous, retina and optic nerve.

    Measured: Evaluated at Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Dec 2010 (estimated)
  2. Study startDec 2010
  3. Primary completionFeb 2016
  4. Study completionFeb 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
175 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01265719
Sponsor's protocol ID
A6111143
Other IDs
PFI-LAT-2009-01, LYNX
Acronym
LYNX
Status last verified
Feb 2018
First submitted
16 Dec 2010
Last updated
3 Feb 2021
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Glaucoma and Ocular Hypertension, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 29 sites in 14 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 29 sites in Italy, Spain, France, Germany, United Kingdom and 9 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 5 Nov 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline to Last Available Observation in Best Corrected Visual Acuity (BCVA) (Snellen or Equivalent) (time frame: Evaluated at Baseline, 6 months, 12 months, 24 months and 36 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2021.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in